company background image
DBP B logo

Double Bond Pharmaceutical International NGM:DBP B Stock Report

Last Price

SEK 0.39

Market Cap

SEK 42.2m

7D

-19.8%

1Y

-52.3%

Updated

24 Dec, 2024

Data

Company Financials

Double Bond Pharmaceutical International AB (publ)

NGM:DBP B Stock Report

Market Cap: SEK 42.2m

DBP B Stock Overview

A pharmaceutical company, engages in the development and commercialization of approaches for the treatment of oncological and infectious diseases. More details

DBP B fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health3/6
Dividends0/6

My Notes

Capture your thoughts, links and company narrative

Double Bond Pharmaceutical International AB (publ) Competitors

Price History & Performance

Summary of share price highs, lows and changes for Double Bond Pharmaceutical International
Historical stock prices
Current Share PriceSEK 0.39
52 Week HighSEK 0.99
52 Week LowSEK 0.26
Beta0.64
1 Month Change-7.08%
3 Month Change3.96%
1 Year Change-52.30%
3 Year Change-57.63%
5 Year Change-88.39%
Change since IPO-91.24%

Recent News & Updates

Recent updates

Shareholder Returns

DBP BSE PharmaceuticalsSE Market
7D-19.8%-0.4%-2.0%
1Y-52.3%-1.8%4.4%

Return vs Industry: DBP B underperformed the Swedish Pharmaceuticals industry which returned -1.8% over the past year.

Return vs Market: DBP B underperformed the Swedish Market which returned 4.4% over the past year.

Price Volatility

Is DBP B's price volatile compared to industry and market?
DBP B volatility
DBP B Average Weekly Movement18.5%
Pharmaceuticals Industry Average Movement8.9%
Market Average Movement5.6%
10% most volatile stocks in SE Market11.4%
10% least volatile stocks in SE Market3.2%

Stable Share Price: DBP B's share price has been volatile over the past 3 months compared to the Swedish market.

Volatility Over Time: DBP B's weekly volatility (19%) has been stable over the past year, but is still higher than 75% of Swedish stocks.

About the Company

FoundedEmployeesCEOWebsite
201410Igor Lokotwww.doublebp.com

Double Bond Pharmaceutical International AB (publ), a pharmaceutical company, engages in the development and commercialization of approaches for the treatment of oncological and infectious diseases. It offers Temodex/SI-053, a therapy to treat malignant brain tumors; and SA033, a therapy to treat cancers in liver. The company is also developing Belopenem for the treatment of bacterial pneumonia.

Double Bond Pharmaceutical International AB (publ) Fundamentals Summary

How do Double Bond Pharmaceutical International's earnings and revenue compare to its market cap?
DBP B fundamental statistics
Market capSEK 42.21m
Earnings (TTM)-SEK 15.37m
Revenue (TTM)SEK 1.13m

37.4x

P/S Ratio

-2.7x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
DBP B income statement (TTM)
RevenueSEK 1.13m
Cost of RevenueSEK 1.92m
Gross Profit-SEK 792.34k
Other ExpensesSEK 14.58m
Earnings-SEK 15.37m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-0.14
Gross Margin-70.28%
Net Profit Margin-1,363.67%
Debt/Equity Ratio0%

How did DBP B perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/24 17:47
End of Day Share Price 2024/12/23 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Double Bond Pharmaceutical International AB (publ) is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution